Becker's Healthcare July 7, 2023
Medicare will provide broader coverage of Leqembi, a drug that has been shown to slow the progression of Alzheimer’s disease, now that the drug has received full FDA approval.
The FDA approved Eisai and Biogen’s medication targeting amyloid plaques in the brain June 6. In a news release, CMS said it would cover the drugs for Medicare patients under certain conditions.
The agency had previously only covered Leqembi and other drugs to treat Alzheimer’s disease for patients in clinical trials.
“With FDA’s decision, CMS will cover this medication broadly while continuing to gather data that will help us understand how the drug works. This is welcome news for the millions of people in this country and their...
Today's Sponsors
Today's Sponsor